Advertisement

Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial

Published:November 08, 2022DOI:https://doi.org/10.1016/j.ejca.2022.09.035

      Highlights

      • Tumour recurrence is common after trimodality therapy for oesophageal cancer.
      • The most common pattern is distant recurrence with or without local recurrence.
      • In 58% of patients, various systemic therapies were initiated depending on histology.
      • Time to recurrence, recurrence sites and systemic therapy correlated with survival.

      Abstract

      Background

      Recurrent oesophageal cancer after the initial curative multimodality treatment is a disease condition with a poor prognosis. There is limited evidence on recurrence patterns and on the optimal therapeutic approach.

      Methods

      We analysed the pattern of disease recurrence and subsequent therapies in patients with recurrent oesophageal cancer based on prospectively collected data within a predefined subproject of the randomised phase 3 trial Swiss Group for Clinical Cancer Research (SAKK) 75/08.

      Results

      Among 300 patients included in the SAKK 75/08 trial, tumour recurrence was observed in 103 patients with a median follow-up of 5.8 years. Locoregional recurrence only was found in 26.2% of the patients, 21.4% of patients had both distant and locoregional recurrence and 52.4% of patients had distant recurrence only. Fifty-nine patients (58%) received at least one line of systemic therapy at recurrence, most commonly oxaliplatin-based combination therapies for adenocarcinoma and single-agent chemotherapy for squamous cell carcinoma. Local therapies, most commonly palliative radiotherapy, were used in 49 patients (48%). Six patients underwent a second curative resection or radiochemotherapy. We found no significant overall survival difference for isolated locoregional recurrence versus distant recurrence (15.1 versus 8.7 months, p = 0.167). In a multivariable Cox regression model, time from oesophagectomy to recurrence and the number of recurrence sites as well as the use of systemic therapy or a second curative local therapy significantly correlated with overall survival.

      Conclusions

      Recurrent oesophageal cancer remains a disease with a poor prognosis and requires multidisciplinary management. A second curative approach for localised disease recurrence may be an option for highly selected patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249
        • Lordick F.
        • et al.
        Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2016; 27: v50-v57
        • Shah M.A.
        • et al.
        Treatment of locally advanced esophageal carcinoma: ASCO guideline.
        J Clin Oncol. 2020; 38: 2677-2694
        • Eyck B.M.
        • et al.
        Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial.
        J Clin Oncol. 2021; 39: 1995-2004
        • Kelly R.J.
        • et al.
        Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.
        N Engl J Med. 2021; 384: 1191-1203
        • Kojima T.
        • et al.
        Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer.
        J Clin Oncol. 2020; 38: 4138-4148
        • Sun J.M.
        • et al.
        Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
        Lancet. 2021; 398: 759-771
        • Hamai Y.
        • et al.
        Treatment outcomes and prognostic factors after recurrence of esophageal squamous cell carcinoma.
        World J Surg. 2018; 42: 2190-2198
        • Parry K.
        • et al.
        Prognosis and treatment after diagnosis of recurrent esophageal carcinoma following esophagectomy with curative intent.
        Ann Surg Oncol. 2015; 22: S1292-S1300
        • Blackham A.U.
        • et al.
        Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.
        J Surg Oncol. 2018; 117: 150-159
        • Blom R.L.
        • et al.
        Survival after recurrent esophageal carcinoma has not improved over the past 18 years.
        Ann Surg Oncol. 2013; 20: 2693-2698
        • Ni W.
        • et al.
        Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma.
        BMC Cancer. 2020; 20: 144
        • Ruhstaller T.
        • et al.
        Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
        Ann Oncol. 2018; 29: 1386-1393
        • Yamashita K.
        • et al.
        Patterns and outcomes of recurrent esophageal cancer after curative esophagectomy.
        World J Surg. 2017; 41: 2337-2344
        • Baumgartner R.
        • et al.
        Utilization and efficacy of palliative chemotherapy for locally advanced or metastatic gastroesophageal carcinoma.
        Anticancer Res. 2020; 40: 965-975
        • Kroese T.E.
        • et al.
        Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
        Eur J Cancer. 2022; 164: 18-29
        • Seyedin S.N.
        • et al.
        Safety and efficacy of stereotactic body radiation therapy for locoregional recurrences after prior chemoradiation for advanced esophageal carcinoma.
        Front Oncol. 2020; 10: 1311
        • Yamamoto T.
        • et al.
        Stereotactic body radiotherapy for pulmonary oligometastases from esophageal cancer: results and prognostic factors.
        Anticancer Res. 2020; 40: 2065-2072
        • Chau I.
        • et al.
        Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study.
        J Clin Oncol. 2021; 39 (LBA4001-LBA4001)
        • Janjigian Y.Y.
        • et al.
        First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
        Lancet. 2021; 398: 27-40
        • Kato K.
        • et al.
        LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study.
        Ann Oncol. 2020; 31: S1192-S1193